Seeing the light


The article 'Making Light Work' (Chemistry World, April 2012, p52) coincided with an alarming Daily Telegraph article relating the near-catastrophic increase in antibiotic resistance due to misuse by the NHS and in agriculture. It seems that big pharma is no longer interested in infection control for two reasons:

1 Any new antibiotic will quickly become ineffective due to acquired resistance.

2 They can make more money with continuous-use drugs to treat obesity, cholesterol and blood pressure than they can make on a 10-day course of antibiotics.

It is no great surprise that they are not interested in the potential of photodynamic therapy (PDT). The argument that they are not engineers is very negative, as in other fields of chemistry, such as cleaning and disinfection of food manufacturing equipment, it is routine for the chemical company to supply and service the dispensing equipment.

PDT is too good an opportunity to waste and there is a moral case for its commercialisation. I wonder if the experts in PDT would consider forming a cooperative organisation whereby professional scientists bought small shareholdings in the venture. I for one would be very happy to contribute a modest percentage of my pension.

M Barrett MRSC
Tewkesbury, UK


Related Content

Chemistry World podcast - October 2013

2 October 2013 Podcast | Monthly

news image

Chemists are helping palaeontologists discover the palette of fossil pigments, and helping toxicologists design greener compo...

The fleeting frontier 

29 April 2016 Premium contentFeature

news image

Andy Extance finds out how chemists are studying processes lasting trillionths of a second – and even less – using laser-...

Most Commented

Chemistry behind the ‘blue man’ unlocked

1 November 2012 Research

news image

Biochemical model suggests that silver ions, not nanoparticles, cause a rare skin complaint

Shadow of Chernobyl

26 April 2016 Critical Point

news image

Mark Peplow takes the long view on the cost of nuclear power